Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)

DBCOND0075300Cardiovascular Diseases Hemic and Lymphatic Diseases

Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA) is the indication for 2 drugs in DrugBank. It is covered by 4 curated, structured indications.

Also known as: Churg-Strauss Syndrome · Allergic granulomatous angiitis · Eosinophilic Granulomatosis With Polyangiitis · Churg Strauss Syndrome · Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Classified under: Cardiovascular Diseases
Hemic and Lymphatic Diseases
Immune System Diseases
Kidney Diseases
Neoplasms
Respiratory Tract Diseases
Signs, Symptoms, and General Pathologies
Skin and Subcutaneous Tissue Diseases
Indicated drugs: Benralizumab
Mepolizumab

Resolves to

Vocabularies

MeSHM0023506ICD-10M30.1SNOMED CT195362002MedDRA10001693UMLSC0008728

What you can answer from here — as of October 23, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

4Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

35Clinical trialsPhase, status and sponsor resolved per trial

4Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account